Physician profile
David J Cunningham
NPI 1659353027
$1,643.24
in general payments reported to CMS, 2019-2025
13 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $94.33 · 2021: $33.02 · 2022: $260 · 2023: $246 · 2024: $409 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $886.77 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $218.89 | 2022-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $150.21 | 2023-2024 | Airsupra, Breztri |
| Dexcom, INC. | $122.00 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $71.77 | 2022-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $46.63 | 2023 | Spravato, Xarelto |
| Novo Nordisk INC | $30.16 | 2024-2025 | Rybelsus, Ozempic |
| Amgen INC. | $27.00 | 2025 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $24.90 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $20.56 | 2024 | Gardasil, Gardasil 9 |
| Vertex Pharmaceuticals Incorporated | $15.94 | 2025 | |
| Tactile Systems Technology INC | $14.93 | 2020 | |
| Pfizer INC. | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.